Medical Startup Filterlex Medical Files for Liquidation in Haifa Court
Medical device startup Filterlex Medical has filed for liquidation at the Haifa District Court after clinical trials on a competitor's product questioned market viability, leaving 1.3 million shekels in debt.
The medical device startup Filterlex Medical, which developed an embolic protection system to reduce stroke risk during transcatheter aortic valve replacement (TAVR), has filed an urgent motion with the Haifa District Court for liquidation proceedings. One of the company's directors and shareholders is renowned entrepreneur Dr. Shimon Eckhouse, founder of Lumenis. In 2012, he established Alon Medtech Ventures, an incubator supporting startups in medical aesthetics, cardiovascular medicine, and other fields.
According to the court filing, submitted via attorney Ahiad Harel, the company never generated revenue. All of its activities were financed through capital raised from investors and R&D grants. "As of the date of this application, the company has ceased all operations. It has no income, no employees, and no funding source whatsoever—no equity, no credit, and no grants. Conversely, its liabilities vastly exceed its assets," amounting to approximately 1.3 million shekels, a significant portion of which is owed to the European Union.
Clinical Findings and Market Impact
The motion explains that in March 2025, results from a large-scale study on a competing product were published, demonstrating low efficacy for products of this type. These findings raised fundamental questions regarding the clinical necessity and commercial potential of embolic protection during cardiac catheterizations. Despite hopes that additional clinical data would present a different outlook, those expectations were disappointed, prompting the board of directors to shutter the operations.
"In Filterlex's case, we encounter two inherent reasons in venture capital that lead startups to insolvency. One is new information—in this case clinical findings—that reveals a market problem. The second is state or international grants—in this case from the European Union—that retroactively reduce grant amounts after the company has already relied on them," stated attorney Ahiad Harel.
Winding Down Operations
Founded in 2015, Filterlex had dozens of shareholders, individuals, and corporate entities, including foreign firms. Dr. Eckhouse and Alon Medtech Ventures together remain the largest shareholders. Before deciding to liquidate, the board reached out to relevant strategic companies to gauge interest in acquiring the company's intellectual property, but these overtures were unsuccessful.
